Abstract:BACKGROUND Laboratory testing of HER2/neu in breast carcinoma has become vital to patient care following the approval of trastuzumab as the first therapy to target the HER2/neu oncoprotein. Initial clinical trials used immunohistochemistry (IHC) to test for HER2/neu overexpression in order to select patients for therapy. Fluorescence in situ hybridization (FISH), which tests for gene amplification, is more specific and sensitive than IHC when either assay is compared with HER2/neu overexpression as determined by Northern or Western blot analysis. Many weak overexpressors on IHC testing are not gene amplified on FISH analysis. Such weak overexpressors may be considered false-positives and raise the question of how best to test for HER2/neu. METHODS The literature was surveyed regarding testing for HER2/neu overexpression in breast carcinomas and alternative testing strategies. RESULTS False-positive results are a significant problem when IHC is exclusively used to test for HER2/neu overexpression. The false-positives are overwhelmingly confined to the group of 2+ positives and do not respond to targeted therapy. In contrast, concordance between IHC and FISH is high when immunostaining is interpreted as either negative or strongly positive (3+). Whereas some recent studies have suggested that FISH may better predict response to anti-HER2/neu therapy than IHC, others have indicated that IHC is as effective a predictor as FISH. IHC is less technically demanding and costly than FISH. CONCLUSIONS IHC analysis of HER2/neu in breast carcinoma is a useful predictor of response to therapy with trastuzumab when strongly positive. Negative immunostaining is highly concordant with a lack of gene amplification by FISH. Most weakly positive overexpressors are false-positives on testing with FISH. Thus, screening of breast carcinomas with IHC and confirmation of weakly positive IHC results by FISH is an effective evolving strategy for testing HER2/neu as a predictor of response to targeted therapy.

Graphene Oxide Hybrid Supramolecular Hydrogels with Self-Healable, Bioadhesive and Stimuli-Responsive Properties and Drug Delivery Application

Ultrastretchable, Self-Adhesive, Strain-Sensitive and Self-Healing GO@DA/Alginate/P(AAc-co-AAm) Multifunctional Hydrogels Via Mussel-Inspired Chemistry

Shear-thinning and Self-Healing Chitosan-Graphene Oxide Hydrogel for Hemostasis and Wound Healing.

An injectable multi-responsive hydrogel as self-healable and on-demand dissolution tissue adhesive

Preparation of self-healable nanocomposite hydrogel based on Gum Arabic/gelatin and graphene oxide: study of drug delivery behavior

Stretchable, Conductive, and Self-Healing Hydrogel with Super Metal Adhesion

Self-healable, super tough graphene oxide–poly(acrylic acid) nanocomposite hydrogels facilitated by dual cross-linking effects through dynamic ionic interactions

A Supramolecular Hydrogel Enabled by the Synergy of Hydrophobic Interaction and Quadruple Hydrogen Bonding

Self-healing and mechanical performance of dynamic glycol chitosan hydrogel nanocomposites

Highly Efficient Self‐Healable and Dual Responsive Cellulose‐Based Hydrogels for Controlled Release and 3D Cell Culture

Stretchable and Self-Healing Graphene Oxide–Polymer Composite Hydrogels: A Dual-Network Design

Self‐healing injectable stimuli responsive polysaccharide hydrogel constructed with dynamic covalent bonds

Rapid self-healing carboxymethyl chitosan/hyaluronic acid hydrogels with injectable ability for drug delivery

Self‐healing mineralized hydrogel scaffolds for stretch‐triggered dye release

Tough, self-healable and tissue-adhesive hydrogel with tunable multifunctionality

Fabrication of self-healing pectin/chitosan hybrid hydrogel via Diels-Alder reactions for drug delivery with high swelling property, pH-responsiveness, and cytocompatibility

Self-Adapting Hydrogel to Improve the Therapeutic Effect in Wound-Healing.

Specific heart muscle disease associated with glycogen storage disease type III: clinical similarity to the dilated phase of hypertrophic cardiomyopathy.

Laboratory testing for HER2/neu in breast carcinoma: an evolving strategy to predict response to targeted therapy.

Thermoresponsive graphene oxide – starch micro/nanohydrogel composite as biocompatible drug delivery system

Pectin-based self-healing hydrogel with NaHCO3 degradability for drug loading and release